-
公开(公告)号：US20180371071A1
公开(公告)日：2018-12-27
申请号：US15582065
申请日：2017-04-28
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
公开(公告)号：US20160060332A1
公开(公告)日：2016-03-03
申请号：US14822329
申请日：2015-08-10
Applicant: Abbvie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
公开(公告)号：US11045480B2
公开(公告)日：2021-06-29
申请号：US16219450
申请日：2018-12-13
Applicant: AbbVie Inc. , AbbVie Biotherapeutics Inc.
Inventor： Kurt C. Gish , Jonathan A. Hickson , Susan Elizabeth Morgan-Lappe , James W. Purcell
IPC: C07K16/28 , C07K16/30 , C07K16/46 , A61K39/395 , A61K31/5517 , A61K38/07 , A61K47/68 , A61K39/00
Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
-
公开(公告)号：US20190031783A1
公开(公告)日：2019-01-31
申请号：US15914856
申请日：2018-03-07
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , C07K16/22 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K45/06 , A61K31/337 , C07K16/28 , A61K39/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
公开(公告)号：US09944720B2
公开(公告)日：2018-04-17
申请号：US14845511
申请日：2015-09-04
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07H21/04 , C12P21/06 , C12N1/12 , C12N1/20 , C12N15/00 , C12N5/00 , C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395 , A61K31/513 , A61K31/7068 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/525 , C07K16/28 , C07K16/00 , A61K39/00
CPC classification number: C07K16/468 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
Patent Agency Ranking
公开(公告)号：US20200255508A1
公开(公告)日：2020-08-13
申请号：US16576078
申请日：2019-09-19
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
公开(公告)号：US10188660B2
公开(公告)日：2019-01-29
申请号：US15363715
申请日：2016-11-29
Applicant: AbbVie Inc. , AbbVie Biotherapeutics Inc.
Inventor： Kurt C. Gish , Jonathan A. Hickson , Susan Elizabeth Morgan-Lappe , James W. Purcell
IPC: A61K38/07 , A61K31/5517 , C07K16/30 , A61K47/06 , A61K39/395 , C07K16/28 , A61K47/68 , A61K39/00
Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
-
公开(公告)号：US20220403052A1
公开(公告)日：2022-12-22
申请号：US17588094
申请日：2022-01-28
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395 , A61K31/513 , A61K31/7068 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/525 , C07K16/28
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
公开(公告)号：US20170151344A1
公开(公告)日：2017-06-01
申请号：US15363786
申请日：2016-11-29
Applicant: AbbVie Inc. , AbbVie Biotherapeutics Inc.
Inventor： Kurt C. GISH , Jonathan A. Hickson , Susan Elizabeth Morgan-Lappe , James W. Purcell
IPC: A61K47/48 , A61K38/07 , A61K31/5517 , C07K16/30
CPC classification number: A61K31/5517 , A61K38/07 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6889 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/77 , C07K2317/92
Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
-
公开(公告)号：US09469688B2
公开(公告)日：2016-10-18
申请号：US14822329
申请日：2015-08-10
Applicant: ABBVIE INC.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07H21/04 , C07K16/22 , C07K14/47 , C07K16/18 , A61K39/395 , A61K45/06 , C07K7/06 , C07K7/08 , A61K39/00
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.023 seconds)
